Drug products: Bisocard, Bisomerck, Bisomyl, Bisoprolol Accord, Bisoprolol Actavis, Bisoprolol Krka, Bisoprolol Mylan, Bisoprolol Orifarm, Bisoprolol Orion, Bisoprolol ratiopharm, Bisoprolol Sandoz, Bisoprolol STADA®, Bisoprolol Teva, Bisoprolol Vitabalans, Bisostad, Emconcor, Emconcor®, Emconcor® CHF, Speridol
ATC code: C07AB07
Substances: bisoprolol, bisoprolol fumarate
Studies about differences between men and women in effect of bisoprolol in atrial fibrillation are lacking.
One clinical study of heart failure treatment with bisoprolol shows women to have a better survival rate than men.
The antihypertensive effect of bisoprolol has shown to be equivalent in men and women.
A study in middle-aged and elderly Japanese patients (29 men, 11 women), routinely treated with 2.5-5 mg bisoprolol once daily, found no effect of age or patient’s sex on renal clearance or volume of distribution .
Results from the multicenter, randomized CIBIS II trial of patients with heart failure with reduced ejection fraction (HFrEF) (2132 men, 515 women) indicate that female sex is a significant independent predictor of survival in patients with congestive heart failure. The risk of all-cause death was lower in women after adjustment for all other significant or known predictors (HR 0.64). There was a lower percentage of death among bisoprolol-treated women compared with men (6% vs. 12%) .
Blood pressure reduction following bisoprolol treatment (5, 10 or 20 mg) have been reported to not be affected by patient's sex .
No studies with a clinically relevant sex analysis regarding adverse effects of bisoprolol have been found.
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2019-05-06
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson